Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director B Lynne Parshall sold 8,334 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $75.00, for a total transaction of $625,050.00. Following the completion of the transaction, the director now owns 61,011 shares of the company’s stock, valued at $4,575,825. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
B Lynne Parshall also recently made the following trade(s):
Get Ionis Pharmaceuticals alerts: On Wednesday, February 27th, B Lynne Parshall sold 8,333 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $70.00, for a total transaction of $583,310.00.Shares of NASDAQ IONS traded up $0.83 during mid-day trading on Thursday, hitting $77.44. The stock had a trading volume of 1,223,900 shares, compared to its average volume of 989,482. The company has a quick ratio of 7.85, a current ratio of 7.88 and a debt-to-equity ratio of 0.53. The company has a market cap of $10.60 billion, a price-to-earnings ratio of 26.16 and a beta of 2.40. Ionis Pharmaceuticals Inc has a 1 year low of $39.07 and a 1 year high of $78.20.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, February 27th. The company reported $2.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $2.20. The business had revenue of $192.00 million for the quarter, compared to the consensus estimate of $159.59 million. Ionis Pharmaceuticals had a net margin of 45.64% and a return on equity of 41.89%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.03) EPS. Equities research analysts anticipate that Ionis Pharmaceuticals Inc will post -0.05 earnings per share for the current year.
Several brokerages recently commented on IONS. Leerink Swann began coverage on shares of Ionis Pharmaceuticals in a research note on Tuesday, November 27th. They issued a “market perform” rating and a $50.00 target price on the stock. TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Thursday, December 6th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Wednesday, January 2nd. ValuEngine raised shares of Ionis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 28th. Finally, BMO Capital Markets lifted their target price on shares of Ionis Pharmaceuticals from $70.00 to $82.00 and gave the stock an “outperform” rating in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $60.57.
A number of institutional investors have recently modified their holdings of the business. Capital Investment Advisory Services LLC bought a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at $91,000. Hanseatic Management Services Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at about $440,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Ionis Pharmaceuticals by 82.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,709 shares of the company’s stock valued at $957,000 after purchasing an additional 8,014 shares during the last quarter. Bank of Montreal Can increased its position in shares of Ionis Pharmaceuticals by 95.2% during the 4th quarter. Bank of Montreal Can now owns 35,651 shares of the company’s stock valued at $1,928,000 after purchasing an additional 17,386 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Ionis Pharmaceuticals by 1.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 51,696 shares of the company’s stock valued at $2,795,000 after purchasing an additional 554 shares during the last quarter. 84.84% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4221733/insider-selling-ionis-pharmaceuticals-inc-ions-director-sells-8334-shares-of-stock.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Read More: What is a Stop Order?
No comments:
Post a Comment